Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis
David A. Mix Barrington, Paulina Haight, Cody Calhoun, Crystal Tubbs, David E. Cohn, Kristin Bixel
Topics & Concepts
MedicineBevacizumabCost effectivenessIncremental cost-effectiveness ratioPembrolizumabDoxorubicinInternal medicineCost-effectiveness analysisOncologyCancerChemotherapyImmunotherapyRisk analysis (engineering)Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersPARP inhibition in cancer therapy